Who Can Be A Defendant In Biosimilar Patent Litigation?

Steptoe associate Ron Vogel co-authored an article titled "Who Can Be A Defendant In Biosimilar Litigation?" for Law360. The article discusses if a party that did not submit an abbreviated biologics license application or an abbreviated new drug application, but will market the biosimilar or generic product after US Food and Drug Administration approval, can be sued for patent infringement or for a declaratory judgment alleging future infringement.